Latest Commercialisation News

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

ClearVue Technologies and LandVac have begun the first real-world deployment of their jointly developed photovoltaic glazing at a Macau hotel. The side-by-side test will measure power generation, thermal performance and cooling demand against legacy single glazing, giving the project its first operating data outside development conditions.

Prescient Therapeutics has raised approximately $6 million through its Share Purchase Plan and a shortfall placement, giving PTX-100 additional funding beyond a key clinical review in December. The next test is whether early results support a move into Phase 2b development.

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Clover Corporation has delivered record FY26 revenue of $97.4 million and a 50% lift in attributable profit, while raising its fully franked final dividend to 1.25 cents per share. The result comes alongside a planned chair transition, with Ian Glasson set to replace retiring chair Rupert Harrington after the 2026 AGM.

Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

Simble Solutions is extending its NanoSensor technology into terrestrial solar monitoring, using its existing SimbleSense and CarbonView platforms as a potential route to commercialisation. The opportunity remains at the benchmark-testing stage, with space-based solar identified as a longer-term possibility rather than an immediate product or revenue stream.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Zeotech Limited (ASX:ZEO) is moving Toondoon toward its first direct-shipping kaolin export after securing a potential A$200 million offtake agreement, while AusPozz™ and zeoteCH₄® produce encouraging trial results. The progress came alongside an A$8.15 million FY26 loss, negative operating cash flow and an acknowledgement that further funding may be required.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.